Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial

Peer Review reports

Original Submission
5 Oct 2022	Submitted	Original manuscript
27 Nov 2022	Author responded	Author comments - Jinsong Yang
Resubmission - Version 2
27 Nov 2022	Submitted	Manuscript version 2
16 Dec 2022	Reviewed	Reviewer Report - Hong Kwan Kim
7 Feb 2023	Reviewed	Reviewer Report
16 Feb 2023	Author responded	Author comments - Jinsong Yang
Resubmission - Version 3
16 Feb 2023	Submitted	Manuscript version 3
Publishing
27 Feb 2023	Editorially accepted
15 Mar 2023	Article published	10.1186/s12885-023-10687-8

Back to article page